ABCL — AbCellera Biologics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703057 ·
Last close
$12.02
Market Cap
$3.90B
52W High
$15.02
52W Low
$2.74
ADV30
5,012,914
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 4,050,000 | — | -58,923,000 | -55,427,000 | 1,307,575,000 | 120,065,000 | 411,555,000 |
| Mar 2026 | 8,315,000 | — | -53,180,000 | -43,165,000 | 1,307,112,000 | 77,063,000 | 369,029,000 |
| Dec 2025 | 44,853,000 | — | -25,266,000 | -8,945,000 | 1,356,950,000 | 128,513,000 | 390,046,000 |
| Sep 2025 | 8,955,000 | — | -73,549,000 | -57,119,000 | 1,355,992,000 | 83,159,000 | 391,954,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-94,937,000
Investing CF
$97,886,000
Financing CF
$25,072,000
CapEx
$-24,734,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.63
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-128,074,000
Inventory
$7,578,000
Receivables
$95,425,000
ST Investments
$420,039,000
EBIT TTM
$-210,918,000
Pretax Income TTM
$-196,769,000
Interest Exp TTM
$42,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,170,000
EBITDA
$-199,960,000
Free Cash Flow
$-46,431,124
Enterprise Value
$2,934,511,872
Total Cash
$540,104,000
Total Debt
$135,616,992
Shares Out
324,047,363
Trailing EPS
$-0.54
Book Value
$2.92
ROE
-17.3%
ROA
-10.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 75,128,000 | -203,213,000 | -146,412,000 | 1,356,950,000 | 390,046,000 | 966,904,000 | -131,295,000 |
| Dec 2024 | 28,833,000 | -301,146,000 | -162,857,000 | 1,360,553,000 | 304,469,000 | 1,056,084,000 | -108,556,000 |
| Dec 2023 | 38,025,000 | -223,052,000 | -146,398,000 | 1,488,094,000 | 335,776,000 | 1,152,318,000 | -43,877,000 |
| Dec 2022 | 485,424,000 | 227,065,000 | 158,519,000 | 1,540,907,000 | 307,630,000 | 1,233,277,000 | 277,360,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$79,208,000
NetIncome TTM
$-143,956,000
OpCashFlow TTM
—
Assets (Latest)
$1,307,112,000
Forward EPS
$-0.71
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.00 · spot: $12.02 · call volume: 2,636 · put volume: 265
Expected Move to 2026-11-20:
±$2.63
(21.88%) —
implied range
$9.39 –
$14.65
· ATM straddle on $12.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | $3.81B | $22.57 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.80B | $78.75 | — |
| BGM | BGM Group Ltd. | $3.79B | $9.96 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.74B | $11.01 | — |
| LEGN | Legend Biotech Corp | $3.64B | $18.71 | — |
News headlines (Yahoo Finance, 1h cache)
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
2026-10-08 20:05 · Yahoo
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
2026-10-01 20:05 · Yahoo
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
2026-09-16 20:05 · Yahoo
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
2026-08-14 22:53 · Yahoo
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
2026-08-13 00:31 · Yahoo
AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?
2026-08-12 07:10 · Yahoo
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal
2026-08-12 06:14 · Yahoo
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results
2026-08-11 21:11 · Yahoo
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
2026-10-01 16:11 · Yahoo
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
2026-09-30 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.